Reported Earnings • Jun 28
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: US$4.01 loss per share (improved from US$13.77 loss in FY 2025). Revenue: US$7.68m (up 107% from FY 2025). Net loss: US$33.2m (loss narrowed 29% from FY 2025). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.3%. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Announcement • Jun 27
Beyond Air, Inc. Provides Revenue Guidance for the Year Ending December 31, 2026 and Year Ending December 31, 2027 Beyond Air, Inc. provided revenue guidance for the year ending December 31, 2026 and year ending December 31, 2027. For the year 2026, the Company announced revenue guidance of $8 million for calendar year 2026, representing 15% growth compared with calendar year 2025.
For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the commercial launch of the second-generation LungFit PH system. Announcement • Jun 23
Beyond Air, Inc. to Report Q4, 2026 Results on Jun 26, 2026 Beyond Air, Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 26, 2026 Announcement • Apr 11
Beyond Air, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule On April 7, 2026, Beyond Air, Inc. (the Company) received a written notification (the Notice) from the staff of the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it no longer satisfies the $1.00 bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the continued listing minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the Bid Price Rule). Based on the closing bid price of the Company's common stock, par value $0.0001 per share (the Common Stock), for the thirty (30) consecutive business days from February 23, 2026 to April 6, 2026, the Company no longer satisfies the Bid Price Rule. While companies are typically afforded a 180-calendar day compliance period to comply with the Bid Price Rule, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split over the prior one-year period. The Company effected a 1-for-20 reverse stock split on July 14, 2025. The Notice stated that the Company's securities will be subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the Panel) by April 14, 2026. Accordingly, the Company intends to timely request a hearing before the Panel, and at which point, such timely request will automatically stay any further suspension or delisting action by Nasdaq pending the Panel's decision. During the appeal process with the Panel, the Common Stock will continue to be listed and trade on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. The Company intends to actively monitor the bid price of its Common Stock and is considering available options to regain compliance with the Nasdaq listing requirements, including such actions as effecting a reverse stock split to maintain its Nasdaq listing. New Risk • Feb 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Price Target Changed • Feb 20
Price target increased by 16% to US$12.00 Up from US$10.33, the current price target is an average from 2 analysts. New target price is 1,088% above last closing price of US$1.01. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$3.88 next year compared to a net loss per share of US$13.77 last year. New Risk • Feb 20
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Market cap is less than US$100m (US$11.4m market cap). Reported Earnings • Feb 16
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: US$0.85 loss per share (improved from US$2.96 loss in 3Q 2025). Revenue: US$2.19m (up 105% from 3Q 2025). Net loss: US$7.34m (loss narrowed 44% from 3Q 2025). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 4.0%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. New Risk • Feb 13
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$37m Forecast net loss in 2 years: US$26m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$26m net loss in 2 years). Market cap is less than US$100m (US$10.7m market cap). Announcement • Jan 27
Beyond Air, Inc. to Report Q3, 2026 Results on Feb 13, 2026 Beyond Air, Inc. announced that they will report Q3, 2026 results Pre-Market on Feb 13, 2026 New Risk • Jan 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$7.02m market cap). Announcement • Dec 22
Beyond Air, Inc., Annual General Meeting, Jan 30, 2026 Beyond Air, Inc., Annual General Meeting, Jan 30, 2026. Location: 900 stewart avenue, suite 301, garden city, new york 11530, new york United States Announcement • Nov 27
Beyond Air, Inc. Announces CFO Changes, Effective December 5, 2025 Beyond Air, Inc. announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company will be assumed on an interim basis by Duke Drewell, the Company’s Controller. Beyond Air has launched a search for a permanent successor. Mr. Larson will serve in an advisory role at the Company through calendar year end 2025 to support a smooth transition. Mr. Larson’s departure is not the result of any disagreements with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. New Risk • Nov 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.85m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$9.85m market cap). Major Estimate Revision • Nov 17
Consensus revenue estimates fall by 36% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$13.4m to US$8.58m. Forecast losses increased from -US$3.47 to -US$3.74 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$12.33 to US$10.33. Share price fell 21% to US$1.38 over the past week. Reported Earnings • Nov 12
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: US$1.25 loss per share (improved from US$5.67 loss in 2Q 2025). Revenue: US$1.82m (up 128% from 2Q 2025). Net loss: US$7.94m (loss narrowed 41% from 2Q 2025). Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 58%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Announcement • Nov 06
Beyond Air, Inc. announced that it expects to receive $32.05 million in funding from Streeterville Capital, LLC Beyond Air, Inc. announced that it has entered into an equity purchase agreement to issue common shares for gross proceeds of $20,000,000 and also entered into a note purchase agreement to issue secured non-convertible promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 for aggregate proceeds of $32,050,000 on November 4, 2025. The transaction includes participation from new investor, Streeterville Capital, LLC. The note will accrue interest at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance and will mature in 24 months following the date of issuance. The equity purchase agreement will terminate on the earlier of the date on which the investor shall have purchased put shares pursuant the agreement equal to the maximum commitment amount, within 24 months after the date of the agreement, written notice of termination by the company to the investor or the date that, pursuant to or within the meaning of any bankruptcy law, the company commences a voluntary case or any person commences a proceeding against the company, a custodian is appointed for the company or for all or substantially all of its property or the company makes general assignment for the benefit of its creditors. The company agreed to pay $50,000 to Streeterville to cover its transaction costs, resulting in the company receiving net proceeds of $32,000,000.
On the same date the company issued secured promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 in its first tranche. Announcement • Oct 23
Beyond Air, Inc. to Report Q2, 2026 Results on Nov 10, 2025 Beyond Air, Inc. announced that they will report Q2, 2026 results on Nov 10, 2025 New Risk • Sep 23
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$42m Forecast net loss in 3 years: US$3.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.0m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue). Market cap is less than US$100m (US$12.3m market cap). Major Estimate Revision • Aug 19
Consensus revenue estimates decrease by 16%, EPS upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$16.0m to US$13.4m. EPS estimate increased from -US$4.08 to -US$4.03 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$19.40 to US$11.20. Share price fell 28% to US$2.29 over the past week. Reported Earnings • Aug 14
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: US$1.53 loss per share (improved from US$5.32 loss in 1Q 2025). Revenue: US$1.76m (up 158% from 1Q 2025). Net loss: US$7.69m (loss narrowed 37% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Announcement • Aug 13
Beyond Air, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2026 Beyond Air, Inc. reaffirmed earnings guidance for the fiscal year ending March 31, 2026. For the period, the company, reaffirmed its revenue guidance of $12 million to $16 million. Announcement • Jul 25
Beyond Air, Inc. to Report Q1, 2026 Results on Aug 12, 2025 Beyond Air, Inc. announced that they will report Q1, 2026 results on Aug 12, 2025 Major Estimate Revision • Jul 23
Consensus EPS estimates upgraded to US$4.31 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.00 to -US$4.31 per share. Revenue forecast unchanged from US$15.9m at last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$45.00 to US$36.60. Share price rose 3.7% to US$3.36 over the past week. Reported Earnings • Jun 18
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: US$0.63 loss per share (improved from US$1.82 loss in FY 2024). Revenue: US$3.71m (up 220% from FY 2024). Net loss: US$46.6m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) exceeded analyst estimates by 7.0%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. New Risk • Jun 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.8m net loss in 3 years). Revenue is less than US$5m (US$3.0m revenue). Market cap is less than US$100m (US$15.5m market cap). Announcement • May 20
Beyond Air, Inc. to Report Q4, 2025 Results on Jun 17, 2025 Beyond Air, Inc. announced that they will report Q4, 2025 results on Jun 17, 2025 Recent Insider Transactions • Mar 18
Independent Director recently bought US$250k worth of stock On the 14th of March, Robert Carey bought around 1m shares on-market at roughly US$0.25 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 11
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: US$0.15 loss per share (improved from US$0.50 loss in 3Q 2024). Revenue: US$1.07m (up 174% from 3Q 2024). Net loss: US$13.0m (loss narrowed 20% from 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Announcement • Feb 07
Beyond Air Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Beyond Air, Inc. announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s minimum bid price rule (Rule 5550(a)(2)). The notification has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to trade on the Nasdaq Capital Market under the symbol "XAIR." Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and, if necessary, by effecting a reverse share split. In a notification letter dated August 8, 2024, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company’s common stock no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until February 4, 2025, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180 calendar day compliance period and submitted a written request to Nasdaq’s staff to afford the Company an additional 180-day compliance period to cure the deficiency, which the Company was granted in a notification letter dated February 5, 2025. If at any time before August 4, 2025, the closing bid price of the Company’s security is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. Announcement • Jan 28
Beyond Air, Inc. to Report Q3, 2025 Results on Feb 10, 2025 Beyond Air, Inc. announced that they will report Q3, 2025 results After-Market on Feb 10, 2025 Announcement • Jan 25
Beyond Air®? Announces LungFit®? PH Receives Market Authorization in Australia Beyond Air, Inc. announced that the LungFit®? PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspiratory limb of the patient breathing circuit of a ventilator in a way that provides a constant concentration of nitric oxide, as set by the user, to the patient throughout the inspired breath. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer®? technology and has already received FDA clearance in the United States and European CE Mark approval. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds. Announcement • Dec 04
Beyond Air, Inc. Receives CE Mark in Europe for the LungFit PH System Beyond Air, Inc. announced European CE mark approval of the LungFit PH system. This CE mark approval allows Beyond Air to market LungFit PH in the European Union and all other countries that recognize this certification. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer technology and has already received FDA approval in the United States. Under the terms of Beyond Air’s existing commercialization agreement with Getz Healthcare for LungFit PH, Getz will make a $1 million milestone payment to Beyond Air upon CE mark certification. In addition, Beyond Air will receive ongoing royalty payments based on LungFit PH net sales. The partnership provides access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore and Vietnam. The specific indications for LungFit PH under CE Mark certification include: 1) the treatment of infants > 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. 2) the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds. Potential customers can visit the LungFit PH website, www.lungfitph.com, for additional information, including the product label, and to sign up for updates. Announcement • Nov 19
Beyond Air, Inc. announced that it has received $3.35 million in funding from Avenue Capital Group, LLC On November 18, 2024 Beyond Air, Inc. closed the transaction. Reported Earnings • Nov 14
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: US$0.28 loss per share (improved from US$0.51 loss in 2Q 2024). Net loss: US$13.4m (loss narrowed 18% from 2Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 1.4%. Revenue is forecast to grow 92% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Major Estimate Revision • Nov 13
Consensus revenue estimates decrease by 56%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$8.69m to US$3.79m. EPS estimate increased from -US$0.944 to -US$0.88 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$3.75 to US$2.50. Share price was steady at US$0.48 over the past week. New Risk • Nov 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 128% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (128% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$4.5m net loss in 3 years). Revenue is less than US$5m (US$1.8m revenue). Market cap is less than US$100m (US$34.7m market cap). Announcement • Oct 30
Beyond Air, Inc. to Report Q2, 2025 Results on Nov 11, 2024 Beyond Air, Inc. announced that they will report Q2, 2025 results After-Market on Nov 11, 2024 Announcement • Oct 10
Beyond Air, Inc., Annual General Meeting, Dec 09, 2024 Beyond Air, Inc., Annual General Meeting, Dec 09, 2024. Recent Insider Transactions Derivative • Aug 25
Chief Executive Officer of NeuroNOS notifies of intention to sell stock Amir Avniel intends to sell 180k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$0.46, it would amount to US$83k. Since December 2023, Amir's direct individual holding has increased from 431.76k shares to 438.03k. Company insiders have collectively bought US$2.9m more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • Aug 13
Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$9.67m to US$9.00m. 2025 losses expected to reduce from -US$1.16 to -US$1.01 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$5.17 to US$4.33. Share price fell 12% to US$0.43 over the past week. Announcement • Aug 07
Beyond Air, Inc. Provides Earnings Guidance for the Year 2025 Beyond Air, Inc. provided earnings guidance for the year 2025, Revenue is expected to be greater than $10 million for Fiscal Year 2025. Announcement • Jul 24
Beyond Air, Inc. to Report Q1, 2025 Results on Aug 06, 2024 Beyond Air, Inc. announced that they will report Q1, 2025 results After-Market on Aug 06, 2024 Announcement • Jul 09
Beyond Air, Inc. announced that it has received $0.128 million in funding On July 9, 2024, Beyond Air, Inc. closed the transaction. The transaction included participation from two investors. Major Estimate Revision • Jul 01
Consensus revenue estimates decrease by 27%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$13.2m to US$9.67m. EPS estimate increased from -US$1.75 to -US$1.15 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$12.60 to US$5.88. Share price fell 60% to US$0.54 over the past week. Price Target Changed • Jun 25
Price target decreased by 55% to US$5.88 Down from US$13.00, the current price target is an average from 4 analysts. New target price is 805% above last closing price of US$0.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$1.82 last year. Announcement • Jun 25
Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025 Beyond Air, Inc. updated revenue guidance for the fiscal year 2025. For the year, the company updated revenue guidance to greater than $10 million, from the previous guidance of $12 million to $16 million. Announcement • Jun 15
Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024 Beyond Air, Inc. announced the appointment of David Webster as Chief Commercial Officer of the Company, effective July 8, 2024. Mr. Webster has successfully developed and executed several commercial strategies for medical devices and therapeutics, primarily in the hospital space. Mr. Webster brings decades of experience in the life sciences industry, including leading several programs through clinical development, regulatory submissions, and global commercialization. Most recently, he served as Chief Executive Officer at Body Vision Medical, a medical device company dedicated to making artificial intelligence (AI)-driven real-time imaging navigation the standard of care for the diagnosis and treatment of endoluminal cancer. As CEO, he led the global commercialization of the Lung Vision system, expanding it into new medical applications. Prior to Body Vision, he spent nearly 18 years at NeuroLogica. During his tenure, he served as NeuroLogica’s Vice President of Global Sales and Marketing leading up to and after the company’s acquisition by Samsung Electronics Co. Ltd. in 2013. Following the acquisition, Mr. Webster served as Chief Marketing Officer and Chief Operating Officer for Samsung NeuroLogica. Mr. Webster holds a Master of Science degree in Business Administration and Management from Troy University and a Bachelor of Arts degree in Psychology from The Citadel. Announcement • May 25
Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024 Beyond Air, Inc. announced that they will report Q4, 2024 results on Jun 24, 2024 Announcement • Mar 23
Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million. Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 9,638,556
Price\Range: $1.66
Discount Per Security: $0.116
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 9,638,556
Transaction Features: Registered Direct Offering New Risk • Mar 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.2% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (US$689k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$78m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$74.8m market cap). Announcement • Mar 22
Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million. Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 9,638,556
Price\Range: $1.66
Discount Per Security: $0.116
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 9,638,556
Transaction Features: Registered Direct Offering Major Estimate Revision • Feb 19
Consensus revenue estimates decrease by 15%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$1.69m to US$1.43m. EPS estimate increased from -US$2.05 to -US$1.95 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$13.00 unchanged from last update. Share price fell 9.8% to US$1.94 over the past week. Announcement • Jan 27
Beyond Air, Inc., Annual General Meeting, Mar 08, 2024 Beyond Air, Inc., Annual General Meeting, Mar 08, 2024, at 16:30 US Eastern Standard Time. Location: Beyond Air, Inc., 900 Stewart Avenue, Suite 301 Garden City New York United States Agenda: To elect seven directors, each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is elected and qualified; to ratify the appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending March 31, 2024; to approve the Sixth Amended and Restated 2013 Equity Incentive Plan to increase the number of shares reserved for issuance by 3,000,000; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Announcement • Jan 19
Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024 Beyond Air, Inc. announced that they will report Q3, 2024 results on Feb 12, 2024 Recent Insider Transactions • Dec 22
Independent Director recently bought US$2.0m worth of stock On the 18th of December, Robert Carey bought around 1m shares on-market at roughly US$1.64 per share. This transaction increased Robert's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.6m more in shares than they have sold in the last 12 months. Major Estimate Revision • Nov 20
Consensus revenue estimates fall by 40% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.86m to US$1.72m. Forecast losses increased from -US$1.90 to -US$2.02 per share. Medical Equipment industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$14.17 to US$12.50. Share price fell 26% to US$1.50 over the past week. New Risk • Nov 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m (US$298k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (US$44.8m market cap). Price Target Changed • Nov 15
Price target decreased by 12% to US$13.00 Down from US$14.83, the current price target is an average from 6 analysts. New target price is 829% above last closing price of US$1.40. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$1.89 next year compared to a net loss per share of US$1.86 last year. 
